Canaccord Genuity Group Begins Coverage on Nuformix (LON:NFX)

Equities researchers at Canaccord Genuity Group began coverage on shares of Nuformix (LON:NFX) in a research note issued to investors on Tuesday,Digital Look reports. The firm set a “buy” rating and a GBX 293 ($3.81) price target on the stock.

Nuformix Trading Up 36.0 %

NFX opened at GBX 0.10 ($0.00) on Tuesday. The stock’s 50-day moving average price is GBX 0.08 and its 200 day moving average price is GBX 0.07. Nuformix has a 12-month low of GBX 0.04 ($0.00) and a 12-month high of GBX 0.30 ($0.00). The firm has a market cap of £1.26 million, a price-to-earnings ratio of -3.10 and a beta of 1.22.

Nuformix (LON:NFX) last posted its earnings results on Wednesday, January 29th. The company reported GBX (0.46) (($0.01)) earnings per share (EPS) for the quarter.

About Nuformix

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.